StockData
Agios Pharmaceuticals, Inc. logo

Agios Pharmaceuticals, Inc. (AGIO) stock

AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/308% above fair value
$29.89−0.26 (-0.86%)

Close on Nov 17, 2026Market cap $1.78BP/E –Yield –

Agios Pharmaceuticals total assets

Total assets on the balance sheet at the end of each period.

Agios Pharmaceuticals's total assets was $1.11B at Jun 30, 2026. For fiscal 2025 it was $1.30B, down 22.0% from the year before. Over ten years it grew 11.9% a year on average. The highest annual figure on record is $1.66B in fiscal 2024.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.30B-22.0%
FY2024Dec 31, 2024$1.66B+77.5%
FY2023Dec 31, 2023$937.12M-24.3%
FY2022Dec 31, 2022$1.24B-13.8%
FY2021Dec 31, 2021$1.44B+68.6%
FY2020Dec 31, 2020$852.95M-4.2%
FY2019Dec 31, 2019$890.74M+3.8%
FY2018Dec 31, 2018$858.46M+39.7%
FY2017Dec 31, 2017$614.40M-0.8%
FY2016Dec 31, 2016$619.09M+47.4%
FY2015Dec 31, 2015$420.07M-14.6%
FY2014Dec 31, 2014$491.90M+144.5%
FY2013Dec 31, 2013$201.21M+46.9%
FY2012Dec 31, 2012$137.01M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.11B-24.7%
Q1 FY2026Mar 31, 2026$1.18B-23.8%
Q4 FY2025Dec 31, 2025$1.30B-22.0%
Q3 FY2025Sep 30, 2025$1.39B-22.7%
Q2 FY2025Jun 30, 2025$1.47B+90.3%
Q1 FY2025Mar 31, 2025$1.56B+83.1%
Q4 FY2024Dec 31, 2024$1.66B+77.5%
Q3 FY2024Sep 30, 2024$1.79B+77.9%
Q2 FY2024Jun 30, 2024$773.06M-28.8%
Q1 FY2024Mar 31, 2024$849.71M-26.2%
Q4 FY2023Dec 31, 2023$937.12M-24.3%
Q3 FY2023Sep 30, 2023$1.01B-14.7%
Q2 FY2023Jun 30, 2023$1.09B-13.4%
Q1 FY2023Mar 31, 2023$1.15B-13.8%
Q4 FY2022Dec 31, 2022$1.24B-13.8%
Q3 FY2022Sep 30, 2022$1.18B-23.4%
Q2 FY2022Jun 30, 2022$1.25B-33.2%
Q1 FY2022Mar 31, 2022$1.34B-46.3%
Q4 FY2021Dec 31, 2021$1.44B+68.6%
Q3 FY2021Sep 30, 2021$1.54B+69.7%
Q2 FY2021Jun 30, 2021$1.87B+92.0%
Q1 FY2021Mar 31, 2021$2.49B+211.2%
Q4 FY2020Dec 31, 2020$852.95M-4.2%
Q3 FY2020Sep 30, 2020$908.45M+30.0%
Q2 FY2020Jun 30, 2020$976.14M+24.5%
Q1 FY2020Mar 31, 2020$799.74M-2.7%
Q4 FY2019Dec 31, 2019$890.74M+3.8%
Q3 FY2019Sep 30, 2019$698.62M-24.8%
Q2 FY2019Jun 30, 2019$783.87M-21.5%
Q1 FY2019Mar 31, 2019$822.13M-21.0%
Q4 FY2018Dec 31, 2018$858.46M+39.7%
Q3 FY2018Sep 30, 2018$929.08M+35.2%
Q2 FY2018Jun 30, 2018$998.24M+31.2%
Q1 FY2018Mar 31, 2018$1.04B+86.6%
Q4 FY2017Dec 31, 2017$614.40M-0.8%
Q3 FY2017Sep 30, 2017$687.20M+2.3%
Q2 FY2017Jun 30, 2017$760.60M–
Q1 FY2017Mar 31, 2017$557.32M–
Q4 FY2016Dec 31, 2016$619.09M–
Q3 FY2016Sep 30, 2016$672.04M–

More Agios Pharmaceuticals figures

See a number that looks wrong?